Joinn Laboratories(China)Co.Ltd Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

Joinn Laboratories(China)Co.Ltd 0.9% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

0.9%

Temettü verimi

0.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.8%
Gelecekteki Temettü Verimi	1.0%
Temettü Büyümesi	20.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	CN¥0.160
Ödeme oranı	-13,617%

Son temettü ve geri alım güncellemeleri

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Jul 28

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Oct 01

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Jul 28

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Apr 04

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 603127 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: 603127 şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 7 yıldır temettü ödemiştir.

Piyasaya Karşı Temettü Getirisi

Joinn Laboratories(China)Co.Ltd Piyasaya Karşı Temettü Getirisi

603127 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (603127)	0.9%
Pazarın Alt %25'i (CN)	0.6%
Pazarın En İyi %25'i (CN)	2.2%
Sektör Ortalaması (Life Sciences)	1.3%
Analist tahmini (603127) (3 yıla kadar)	1.0%

Önemli Temettü: 603127 'in temettüsü ( 0.9% ), CN piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 0.55% ) daha yüksektir.

Yüksek Temettü: 603127 'in temettüsü ( 0.9% ), CN piyasasındaki temettü ödeyenlerin en üst %25'ine ( 2.17% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 603127 temettü ödüyor ancak şirket kâr etmiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Mevcut nakit ödeme oranı ( 86.6% ) ile 603127 'un temettü ödemeleri nakit akışları tarafından karşılanmaktadır.

Joinn Laboratories(China)Co.Ltd Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd. Approves Final Dividend in Cash for the Year Ended December 31, 2021, Payable on 23 August 2022

Joinn Laboratories (China) Co.,Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021, Payable on 23 August 2022

Joinn Laboratories (China) Co.,Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Joinn Laboratories(China)Co.,Ltd. Announces Resignation of Yao Dalin as Executive Director and Vice General Manager

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 27%

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Dividend of CN¥0.16 announced

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Consensus revenue estimates fall by 19%

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Price target decreased by 7.2% to CN¥25.92

Price target decreased by 7.3% to CN¥28.66

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Consensus EPS estimates fall by 27%

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 700%

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 10%

Price target decreased by 11% to CN¥33.30

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to CN¥37.55

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased by 8.7% to CN¥57.93

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.4% to CN¥70.19

Price target increased by 7.4% to CN¥76.57

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Price target decreased to CN¥71.30

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Price target increased to CN¥86.02

Insider recently sold CN¥60m worth of stock

Now 21% undervalued after recent price drop

Price target decreased to CN¥74.80

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)